These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 11367500)

  • 1. The rules for successful HAART (highly active antiretroviral therapy).
    Newsline People AIDS Coalit N Y; 1998; ():30. PubMed ID: 11367500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stop-and-go therapy.
    Posit Aware; 2000; 11(1):23. PubMed ID: 11366338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Program increases HAART adherence in HIV patients.
    AIDS Alert; 1999 Mar; 14(3):31-2. PubMed ID: 11366214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV and HAART in 1997. Highly active antiretroviral therapy.
    Klaus BD; Grodesky MJ
    Nurse Pract; 1997 Aug; 22(8):139-42. PubMed ID: 9279851
    [No Abstract]   [Full Text] [Related]  

  • 6. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taking a break from therapy.
    TreatmentUpdate; 1999 Jul; 11(5):2-3. PubMed ID: 11366927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
    Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
    AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
    Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
    J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
    Lima VD; Johnston K; Hogg RS; Levy AR; Harrigan PR; Anema A; Montaner JS
    J Infect Dis; 2008 Jul; 198(1):59-67. PubMed ID: 18498241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New study: stopping therapy.
    Vazquez E
    Posit Aware; 1999; 10(4):25. PubMed ID: 11366800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
    Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
    Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in Botswana.
    Vriesendorp R; Cohen A; Kristanto P; Vrijens B; Rakesh P; Anand B; Iwebor HU; Stiekema J
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1115-21. PubMed ID: 17882408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How compliant are patients on HAART?
    AIDS Alert; 1999 Jan; 14(1):11. PubMed ID: 11366087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HAART with didanosine once versus twice daily: adherence and efficacy.
    Roca B; Lapuebla C; Vidal-Tegedor B
    Int J Infect Dis; 2005 Jul; 9(4):195-200. PubMed ID: 15964537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial antiretroviral drugs.
    Rojo P; Gonzalez-Tome MI; Ramos JT
    Pediatr Infect Dis J; 2007 Dec; 26(12):1167; author reply 1167. PubMed ID: 18043466
    [No Abstract]   [Full Text] [Related]  

  • 19. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.
    Torti C; Moretti F; Uccelli MC; Tirelli V; Quiros-Roldan E; Gargiulo F; Carosi G
    Med Sci Monit; 2003 Apr; 9(4):CS16-9. PubMed ID: 12709675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of recent guidelines for antiretroviral treatment of HIV-infected children.
    Oleske JM
    Top HIV Med; 2003; 11(6):180-4. PubMed ID: 14724326
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.